Loading…
← CockpitCompetitor Analysis › DNTH Dianthus Therapeutics, Inc.Open in the cockpit ↗

Dianthus Therapeutics, Inc.DNTHCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops complement inhibitor antibodies for severe autoimmune and rare inflammatory diseases.

Momentum weak 39
Mkt cap
$4.73B
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$69.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-58.5 pp
WACC 12.4%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$83.98
1D-3.5%
1W-6.0%
1M+6.6%
3M-23.3%
6M-5.3%
YTD+103.8%
1Y+103.1%
ATR %5.6%
Beta0.95
52w lowhigh28.8% off high

What Dianthus Therapeutics does

Develops complement inhibitor antibodies for severe autoimmune and rare inflammatory diseases.

Has no approved product and no sales; it funds its trials by selling new shares and could later be paid through sales of an approved drug or through licensing deals. It became a public company in 2023 by merging with Magenta Therapeutics, an already-listed biotech.

Products and services

  • DNTH103 (complement C1s inhibitor)
  • Pipeline in myasthenia gravis and CIDP

Customers

  • Neurology and autoimmune disease specialists (post

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Complement-targeted antibody…

What could go right

  • Pivotal trial readouts and potential approval
  • Complement-disease pipeline expansion

What could go wrong

  • Clinical trial failure risk
  • Competitive complement-inhibitor landscape

Moat: none (IP / patents). Clinical-stage biotech with patent-protected antibody candidates but no approved products or revenue yet.

Headquarters: New York City, US · Founded: 2022 · Employees: 92

Named competitors

Dianthus Therapeutics at a glance

Size Dianthus Therapeutics (DNTH) is a United States Health Care company (Biotechnology) with a market value of $4.73B, the 1216th largest of 3,085 United States companies the cockpit tracks. Shares closed at $83.98 on 18 Nov 2026.

Performance Over six months the shares fell 5.3%, against +2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue fell 11.7% over the last twelve months (peer median +8.3%); the operating margin is -8,683.9% (peer median -15.6%).

Valuation It trades at 1,432.1× enterprise value to sales against a peer median of 12.7× (2nd most expensive of 16).

Capital Return on invested capital runs 58.5 points below its cost of capital (12.4% WACC).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 101DNTH 94
Six months, rebased to 100: Dianthus Therapeutics against the median of its 20 peers (local-currency closes).

Dianthus Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.72M$2.04M$6.24M$2.83M$6.42M
Revenue growth—-67%+121%-56%—
Gross profit$2.33M$1.61M$5.82M$2.47M$6.27M
EBITDA-$236M-$178M-$101M-$47.8M-$29.6M
Net income-$202M-$162M-$85.0M-$43.6M-$28.5M
Free cash flow-$176M-$129M-$78.3M-$37.0M-$29.2M
Capital expenditure$697,000$213,000$105,000$110,000$139,000
Total debt$1.21M$1.39M$1.49M$585,000$788,000

Quarterly statements and history in the cockpit →

Dianthus Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%3347COGTADPT002252EWTX0006611530300122603392ANTHEMCAI6696CRSPSRRKTNGX6127ARWRRLAYABCLIRONDNTH6-month return →1-month return →
Up and to the right = strong over both horizons. Dianthus Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×500×1,000×1,500×3347ADPT0022520006611530ANTHEMCAICRSPARWRRLAYABCLDNTHRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dianthus Therapeutics is the large dot.

Dianthus Therapeutics competitors and peer comparison

Head to head with its named competitors (DNTH vs AZN.L vs ARGX vs IMVT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Dianthus Therapeutics DNTH$4.73B-5%-12%-8,684%1,432.1×n/a
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%
argenx SE Sponsored ADR ARGX$59.1B+17%+71%29%10.3×11.7%
Immunovant IMVT$6.86B-7%n/an/an/an/a
Johnson & Johnson JNJ$656B+20%+8%26%6.9×3.7%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%5.4×-1.1%
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Annexon ANNX$671M-30%n/an/an/an/a

How Dianthus Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dianthus Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureDNTHPeer medianRank in peer set
1-month return+6.6%-7.7%5th highest of 21
6-month return-5.3%+2.0%8th lowest of 21
Distance from 52-week high-28.8%-33.1%9th highest of 21
Revenue growth (TTM)-11.7%+8.3%7th lowest of 16
Operating margin-8,683.9%-15.6%2nd lowest of 16
EV / Sales1,432.1×12.7×2nd most expensive of 16
ROIC minus cost of capital-58.5 pp-9.8 pp2nd lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a
Hangzhou Tigermed Consulting 3347.HKHong Kong$4.75B0%+22%10%4.8×25.4%+15.6%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%15.8×n/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%5.4×n/an/a
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%2.8×32.4%+7.1%
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
JOINN Laboratories (China) 6127.HKHong Kong$3.70B+6%+17%-4%12.4×n/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a

Questions

Who are Dianthus Therapeutics's main competitors?
Named competitors: Alexion (AstraZeneca) (AZN.L), Argenx (ARGX), Apellis Pharmaceuticals (private or unlisted), Immunovant (IMVT), UCB (private or unlisted), Johnson & Johnson (JNJ). The cockpit's measured peer set (industry) also includes Hangzhou Tigermed Consulting (3347.HK), Cogent Biosciences (COGT), Adaptive Biotechnologies (ADPT), Shanghai RAAS Blood Products (002252.SZ), Edgewise Therapeutics (EWTX), Changchun High-Tech Industry (Group) (000661.SZ).
Is Dianthus Therapeutics expensive compared with its peers?
On ev / sales it trades at 1,432.1× against a peer median of 12.7×, 2nd most expensive of 16 in its peer set.
How has Dianthus Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -5.3% against +2.0% for the median peer; over one year +103.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.